WUXI.F Stock Overview
An investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
WuXi AppTec Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥5.88 |
52 Week High | CN¥11.60 |
52 Week Low | CN¥3.74 |
Beta | 0.81 |
11 Month Change | 55.47% |
3 Month Change | 38.93% |
1 Year Change | n/a |
33 Year Change | -72.01% |
5 Year Change | n/a |
Change since IPO | -52.61% |
Recent News & Updates
Recent updates
Shareholder Returns
WUXI.F | US Life Sciences | US Market | |
---|---|---|---|
7D | 55.5% | 2.8% | 2.2% |
1Y | n/a | 2.9% | 31.7% |
Return vs Industry: Insufficient data to determine how WUXI.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how WUXI.F performed against the US Market.
Price Volatility
WUXI.F volatility | |
---|---|
WUXI.F Average Weekly Movement | n/a |
Life Sciences Industry Average Movement | 8.8% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WUXI.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine WUXI.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 38,134 | Ge Li | www.wuxiapptec.com |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
WuXi AppTec Co., Ltd. Fundamentals Summary
WUXI.F fundamental statistics | |
---|---|
Market cap | US$19.42b |
Earnings (TTM) | US$1.11b |
Revenue (TTM) | US$5.31b |
17.8x
P/E Ratio3.7x
P/S RatioIs WUXI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
WUXI.F income statement (TTM) | |
---|---|
Revenue | CN¥38.50b |
Cost of Revenue | CN¥22.86b |
Gross Profit | CN¥15.64b |
Other Expenses | CN¥7.57b |
Earnings | CN¥8.06b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 2.79 |
Gross Margin | 40.61% |
Net Profit Margin | 20.94% |
Debt/Equity Ratio | 10.1% |
How did WUXI.F perform over the long term?
See historical performance and comparison